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THE SYSTEMIC AND INTERPERSONAL BARRIERS TO HIV PrEP ACCESS 




There is limited data regarding human immunodeficiency virus (HIV) prevalence 
among transgender individuals. Further complicating the absence of knowledge, 
transgender women are often conflated with men who have sex with men (MSM). 
Approximately half of transgender men and women who live with HIV are from the 
Southern region of the United States (US). While transgender women are more likely to 
contract HIV compared to transgender men, approximately two-thirds of transgender 
individuals have not tested for HIV, likely leading to underreporting. Among the 14% of 
transgender women diagnosed with HIV/AIDS in the US, 44% are Black, (despite 
representing only 25% of the population in the US), and 26% are Latinx, which is four 
times the prevalence rate of White transgender women (7%). Pre-exposure prophylaxis 
(PrEP) is an HIV prevention method in which individuals at risk for HIV can take a daily 
pill to reduce the risk of contracting HIV. Previous PrEP research has been conducted 
among transgender women and men, Black and Latinx MSM, and cisgender women. 
However, there is limited research on barriers to PrEP adoption among Black or Latinx 
transgender women and men. This study aims to evaluate barriers to PrEP interest and 
adoption to better address issues faced by Black and Latinx transgender men and women. 
A meta-analysis of HIV prevalence among transgender women identified a need for HIV 
	
	 vi 
prevention as transgender women are at high risk for HIV. In a study with a sample of 
233 transgender women in the US, only 13.7% were aware of PrEP (Wilson et al., 2016). 
Among studies including Black and Latinx transgender women, barriers to PrEP adoption 
included: medical mistrust, lack of knowledge (e.g., side effects), PrEP stigma among 
community members and doctors, perceived/actual discrimination regarding having sex 
with men by providers and advertisements, concerns regarding interactions with hormone 
therapy, and objections by romantic partners. Social support following PrEP use 
disclosure is associated with greater self-esteem for one’s transgender identity and greater 
likelihood of PrEP use. Among black and Latinx trans men, barriers to PrEP included 
lack of support from family and discrimination. Other barriers that Black and Latinx 
cisgender women face, which may be applicable to Black or Latinx transgender women 
and men, are lower educational attainment, income, decreased access to healthcare 
services, medical mistrust, language barriers, racial bias from medical providers, and lack 
of social support. Awareness of PrEP has been lower among those who are less educated 
and whose primary care providers are unaware that they have sex with men. One study 
showed that those with lower income and less than a high school education were 
associated with poorer medication adherence and greater risk of death even when 
controlling for HIV treatment. In another study examining potential barriers to PrEP 
acceptability and adherence, efficacy and side effects were notable barriers to PrEP 
initiation among 78% of MSM and transgender women participants, which were more 
commonly reported among Black compared to White participants. Given the dearth of 
research among Black and Latinx trans men and women regarding barriers to PrEP 
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adoption, it is essential to evaluate systemic and interpersonal barriers to PrEP access that 
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There is limited data regarding human immunodeficiency virus (HIV) prevalence among 
transgender individuals; further complicating the lack of data is the tendency to collapse 
data on transgender women with men who have sex with men (MSM) (Sevelius et al., 
2016; Thomann et al., 2018). While transgender women are more likely to contract HIV 
compared to transgender men, approximately two-thirds of transgender individuals have 
not tested for HIV leading to a high likelihood of underreporting (Hendricks & Testa, 
2012; Meyer, 2003). Approximately half of transgender men and women who live with 
HIV are from the southern United States (e.g., Texas, Georgia, Mississippi). During 
2009-2014, there were 2,351 diagnoses of HIV infection. Of new infections, 84% were 
transgender women (male-female), 15.4% were transgender 
 
FIGURE 1. 





men (female-to-male) and 0.7% were an additional gender identity (e.g., gender queer, 
bi-gender). One study researching HIV prevalence in the United States found that among 
the 14% of transgender women diagnosed with HIV/AIDS, 44% were Black (despite 
representing only 25% of the population in the US), and 26% were Latina, which is four 
times the prevalence rate of White transgender women 7% (Figure 1; Clark et al., 2017)  
 
HIV History 
The HIV virus was first identified in the early 1980s when a large number of MSM were 
being diagnosed with uncommon diseases such as rare cancers and bacterial or fungal 
infections found individuals with a weak immune system (Sharp & Hahn, 2011). One of 
these infections included Kaposi’s Sarcoma, a form of cancer in which patients develop 
large purple lesions on the skin (Greene, 2007). During the early years of the HIV 
epidemic, health care providers struggled to identify the cause of many of the infections 
these young men were experiencing. Because these infections were most commonly seen 
in gay men, this type of disease course was deemed the “gay plague” (Greene, 2007, 
p.94). At first glance, physicians believed HIV infection was a collection of multiple 
diseases that were caught from certain lifestyle choices, and consequently over worked 
the immune system. There were multiple theories surrounding the cause of HIV that 
traced back to stigmatizing and criticizing behavior of MSM. These theories included 
adverse reactions to semen, the use of amyl nitrites (i.e., poppers), fungal infections that 
were unknown, and having sex with multiple people. (Greene, 2007). The uncertainty of 
how the infection was being transmitted provided little effort towards preventative 
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efforts, thus blood banks were not testing their blood for HIV. Patient Elizabeth Glaser 
was a prominent case in which she was transfused blood from an HIV positive donor, and 
later passed HIV to her child during birth. Glaser’s incident sparked an interest for more 
research on HIV and the creation of Elizabeth Glaser Pediatric AIDS Foundation 
(Greene, 2007). 
 
On a national level, efforts for HIV preventative treatment strategies were lagging behind 
public awareness. After years of silence and inaction, President Reagan finally addressed 
the HIV epidemic in the United States by launching the Presidential Commission on the 
HIV Epidemic. Though futile, this commission effort sought to provide hundreds of 
recommendations, more HIV testing, legal support for HIV positive people, advocating 
for treatment and prevention of drug abuse, and more jobs in the field of HIV 
preventative care (Yehia & Frank, 2011). However, Reagan’s efforts were ultimately 
ineffective as the commission’s guidelines were not strictly enforced and often ignored. 
After mounting public pressure, the next president, Bill Clinton, took some further action 
on the HIV pandemic, launching the National AIDS Strategy. President Clinton outlined 
six goals which were increase HIV related research, reduce HIV infections, offer HIV 
positive people with medical services, eradicate discrimination based on HIV status, 
support efforts of HIV preventative treatment on a national scale, and lastly have the 





HIV is a lentivirus with two variants, HIV-1 and HIV-2 (Sharp & Hahn, 2011). There is 
evidence that supports that HIV was a product of many cross-species infections of the 
simian immunodefiency virus, which is exclusive to primates. A connection to primates 
was made between another variant of the HIV virus found in Africa, known as the HIV-2 
virus. There was an antigenic difference between this virus and the HIV-1 virus found in 
patients of North America (Sharp & Hahn, 2011). There were many species identified for 
the zoonotic transfer of HIV to humans (Figure 2; Sharp & Hahn, 2011). 
 
HIV affects the host’s immune system, specifically depleting the population of CD4+ T-
cells, which play a critical role in the integrity of the immune system (Hutchinson, 2001). 
FIGURE 2. Origins of Human AIDS Viruses (Sharp & Hahn, 2011).  
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The mode of transmission of HIV is through bodily fluids such as semen, blood, or fluids 
exchanged during birth. HIV is not known to be transmitted through surfaces, objects, 
and there is minimal risk of transmitting the disease from mouth to mouth, as saliva may 
carry antibodies that could defend against HIV and provide a negative status 
(Hutchinson, 2001). HIV can develop into acquired immune deficiency syndrome (AIDS) 
which is defined as having less than 200 cells/mm3 CD4+ count in the blood (Battistini 
Garcia & Guzman, 2021). The size and shape of HIV is spherical and has a length of 100 
nm. The molecular structure consists of a double envelope made up of lipids that contain 
protein spikes. The spikes contain four molecules of the protein gp120 and four 
molecules of gp41. Within the envelope is a cone shape capsid. The capsid is made up of 
a protein p24, containing the genetic material, an essential component for its replication  
within the host. In addition to these viral components, the HIV virus contains two RNA 
strands that are 9200 bases long.  
 
The viral machinery that aid in its replication are also within the viral core, which are 
integrase, protease, ribonuclease, p6 and p7 protein (“Human Immunodeficiency Virus 
(HIV),” 2016). The integrase protein, p32 functions to insert the DNA into the genome of 





The ribonuclease is essential for degrading the RNA in the viral DNA-RNA complex. 
The p6 and p7 aid in particle release of the virus and formation of the nucleoprotein/RNA 
complex respectively (“Human Immunodeficiency Virus (HIV),” 2016).  
 
HIV Life Cycle 
The HIV life cycle consists of various stages when infecting the cells of the host that 
have been used as important targets for therapy (Figure 4, HIV Replication Cycle | NIH, 
2018). In the first phase of the HIV life cycle, the virus recognizes the target cell with the 
appropriate surface protein. The HIV virus target protein is CD4, an important marker for 
T-cell helper cells (Turner & Summers, 1999). In addition to binding to the CD4 protein, 
FIGURE 3 HIV Structure “Human Immunodeficiency Virus (HIV),” 2016 
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HIV also binds two co-receptors that provide a stronger binding interaction. These two 
co-receptors are the CCR5 and CXCR4 chemokine receptors (Turner & Summers, 1999). 
Following binding into the host cell, the virus’s coat releases the reverse transcriptase to  
replicate the RNA strand into DNA, forming a RNA/DNA complex. This is necessary 
step for the viral DNA to infect into the host cell (Turner & Summers, 1999). Via the 
protein integrase, the viral DNA inserts itself into the host genome, making it a 
permanent a permanent infection  (Hutchinson, 2001).  
 
The late phase of the HIV cycle is marked by the production of mRNA molecules. The 
mRNA molecules are splices by regulatory proteins that allow synthesis of other proteins 
that are translocated within the cell (Turner & Summers, 1999). Translocation out of the 
nucleus and into the endoplasmic reticulum (ER) is an important step in the HIV life 
cycle, and one of the trademarks of the disease. The ER assists in posttranslational 
modifications, thus other proteins are present such as CD4, which may interfere with the 
assembly of HIV virions. The HIV virus is able to avoid premature binding in the ER by 
translating the protein Vpu, which binds the CD4 molecule and prepares it for 
degradation. This feature of the HIV molecule allows it to avoid detection from the host 
immune system as CD4 is an important target protein in creating an adaptative immune 
response (Parnes, 1989; Turner & Summers, 1999). Following modifications in the ER, 
the HIV virus can assemble it’s viral particles and release its progeny from the cell, 









The HIV mutation rate is extraordinarily high, due to the fact that the HIV replicates 
many copies of itself inside the host cell (Hutchinson, 2001; Nomaguchi et al., 2018). 
The mutation of HIV has been suggested to serve to avoid detection of the host immune 
system and drug resistance. Many of these mutations include substitutions, frameshifts,  
but mainly nucleotide changes are suggested to be the cause of these resistances seen 
with the HIV virus (Nomaguchi et al., 2018).  
 
HIV Medication 
There are various parts of the HIV life cycle that are targeted for therapeutic use, for 
example, entry of the HIV virus into the cell. The virus particle uses protein gp120 to 
bind to the CD4 surface receptor, which pharmaceutical companies have exploited, by 
using an antibody that can bind to gp120, thus neutralizing the interaction (Engelman & 
Cherepanov, 2012). However there are drawbacks to using the antibodies, as they are 
strain specific, which suggests that a more polyclonal antibody should be used to bind 
different sites against gp120 or other sites of the interaction between gp120 and CD4 to 
destabilize it (Engelman & Cherepanov, 2012). In addition, mutations can also prevent 
gp120 inhibitors from binding to these target sites. Other target sites to prevent viral entry 





Other sites used for targets of blocking HIV include post membrane fusion, in which the 
viral core of HIV penetrates the cell. Once HIV virus enters the cell, the virus uncoats 
itself and signals reverse transcriptase, an essential component of the HIV life cycle. 
Scientists developed a molecule, PF‑3450074, that can cause premature uncoating, and 
destabilize the interactions and elicit an innate immune response (Engelman & 
Cherepanov, 2012). The synthesis of viral DNA poses another target for antiviral therapy, 
in which nucleotides can be added into the reverse transcriptase activity and cause chain 
termination (Engelman & Cherepanov, 2012).  
 
These chain terminators are called nucleoside reverse transcriptase inhibitors. These 
molecules are added to viral DNA but can no longer be elongated due to the lack of the 
3’hydroxyl group. A similar molecule can also provide similar effects to nucleoside 
based inhibitors, called non-nucleoside reverse transcriptase inhibitors (Arts & Hazuda, 
2012; Engelman & Cherepanov, 2012). The mechanism of action for these inhibitors is to 
bind to other sites of the interaction between reverse transcriptase and the produced DNA 
molecule. These targets sites are enzymatic residues, that when bound to a non-
nucleoside reverse transcriptase inhibitor, a conformational change occurs in the reverse 
transcriptase and DNA complex that destabilizes it (Arts & Hazuda, 2012; Engelman & 
Cherepanov, 2012). The resistances that occur in HIV to avoid these inhibitors include 
excising the nucleoside that lacks the 3’ hydroxyl group through an adenosine 5'-




Upon the insertion of viral DNA into the host cell by integrase, integrase catalyzes the 3’ 
end of the viral DNA for processing (Arts & Hazuda, 2012). These steps in the viral cycle 
provide other opportunities for exploitation of viral inhibitors. These integrase inhibitors 
binds to the integrase and viral DNA complex and destabilize the ions essential for DNA 
insertion into the host genome (Arts & Hazuda, 2012). The mutations that occur to 
prevent these integrase inhibitors from functioning occur within the enzymatic binding 
pockets at specific residues (Arts & Hazuda, 2012; Engelman & Cherepanov, 2012). 
The other type of therapeutic agents affects the final step of the HIV life cycle which is 
the maturation of the virus.  
 
Once the virus has assembled itself within the cell, it is released from the cell through the 
process of budding (Turner & Summers, 1999). Once the virus exits the cell, proteolytic 
cleavage occurs in which a mature virus particle is produced (Turner & Summers, 1999). 
The class of inhibitors that target this step in the HIV cycle are protease inhibitors. The 
specific mechanism of action is to bind the protease to prevent the cleavage of the viral 
precursor, resulting in degradation and non-functional virus particle (Arts & Hazuda, 
2012). Similar to other classes of therapeutic agents, protease inhibitors face resistance 
from the HIV virus, in which variations of nucleotide sequence of the protease are 
changed, preventing binding of the inhibitor (Arts & Hazuda, 2012).  
 
The current standard for HIV care to reduce the levels of virus in HIV positive  
individuals is highly active antiretroviral combination therapy (HAART), which includes 
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at least two types of nucleoside reverse transcriptase inhibitor and either one non-
nucleoside reverse transcriptase inhibitor or protease inhibitor (Yeni, 2006). The goal of 
this method of preventative treatment is to reduce viral load and increase the amount of 
CD4+ cells within the body (Yeni, 2006). This form of therapy has been proven to reduce 
the death rate of HIV positive patients, as it targets multiple sites of the HIV cycle and 
combats the outcome of resistances occurring from random mutation, resulting in a better 
outlook for patients (Yeni, 2006). While there are promising effects of this form of 
therapy, there is evidence that HAART has side effects such as inflammation of the liver, 
lactic acidosis, and mitochondrial toxicity (Yeni, 2006).  
 
HIV Pathology 
When the HIV virus enters the body, it takes at least two weeks for symptoms to be 
present, and at times there are no symptoms (Naif, 2013). The symptoms that patients 
develop during the early stages of infection are swollen lymph nodes, fever, and lethargy 
(Sotrel & Dal Canto, 2000). During this stage, the virus may remain in the body and 
silently replicate, with the host becoming asymptomatic. The level of virus will continue 
to rise and conversely, decrease the amount of CD4+ cells within the body (Naif, 2013). 
In addition to the increase of virus within the body, cytotoxic T cells and antibodies 
increase in number to combat the infected CD4+ cells, consequently depleting the 
amount of CD4+ cells and weakening the immune system (Figure 5, Omari & Ouifki, 
2021; Sotrel & Dal Canto, 2000). During the late stages of the virus, when CD4+ cells 
become very low in the body, the 
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body is susceptible to opportunistic infections such as Kaposi’s sarcoma, pneumococcal 
bacterium, and toxoplasmosis (Chaisson et al., 1998). In one study, the rate of mortality 
was increased in those who did experience opportunistic infections as well as dementia, 
or wasting (Chaisson et al., 1998). In most of the patients with opportunistic infections, 
the viral load and replication rate had increased, which may have been a result of 
adherence to medication or resistant to antiretroviral therapy (Chaisson et al., 1998).  
 
There is evidence to suggest that the symptoms of HIV can be exacerbated by external 
psychosocial factors such as internalization of attitudes towards people who are HIV 
positive and stress. These stressors include the fear of being stigmatized, test results, and 
experiencing HIV related symptoms during the disease course (Earnshaw et al., 2015). 
Other instances of lowered immune function were found in individuals who experienced 
Figure 5. Viral Load and effects on CD4+ Count (Omari & Ouifki, 2021) 
	
14 
depressive symptoms. The quality of life of participants has been studied among HIV 
positive participants, in which participants who reported more depressive symptoms also 
had lower levels of cytotoxic T cells (Reis et al., 2011).  
 
HIV Stigma 
Previous studies have explored the possible effects of HIV stigma, that have been 
identified as a barrier to people living with HIV (Rao et al., 2012). HIV stigma has been 
linked with poor health outcomes, poor medical adherence, lower levels of seeking 
preventative treatment among HIV positive people (Rao et al., 2012). A study on a 
population from Uganda explored the correlation between internalized HIV stigma and 
the outcome of revealing their HIV status. The study results showed that those with 
higher levels of internalized stigma regarding their status were more likely to avoid 
disclosing their HIV status (Tsai et al., 2013).  
 
Similarly, in a study done in India, it was noted that the fear and shame of being HIV 
positive prevented people from disclosing their HIV status to others. Additionally, these 
participants were found to have a lower adherence for their medication (Ekstrand et al., 
2018). The participants in the study disclosed their experiences seeking treatment in 
which their health care providers denied them access and providers disclosing their 
patients status with others (Ekstrand et al., 2018). In addition to the general fear of 
negative public attitudes towards HIV positive people, there were gender differences 
found between men and woman (Ekstrand et al., 2018). One study explored the effects of 
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HIV stigma in mothers from Saharan Africa who were HIV positive. Their results 
demonstrated that mothers were less willing to seek preventative treatment during 
pregnancy resulting in transmission of the virus to their newborns (Arrey et al., 2017). 
The participants in this study described reasons of being stigmatized due to being the 
reason for spreading HIV and other people being uneducated about HIV transmission and 
prevention (Arrey et al., 2017). The participants also described the forms of stigma they 
experienced. For example being humiliated, denied access to care by health professionals, 
and healthcare professionals taking unnecessary steps when seeing HIV positive patients 
(e.g. HIV positive patients being seen last at clinics to avoid contamination with HIV 
negative patients) (Arrey et al., 2017).   
 
HIV Prevalence 
HIV is an autoimmune disease which can develop into AIDS and other opportunistic 
infections if left untreated. (CDC, 2020). An estimated 1.2 million people in the United 
States had HIV at the end of 2018 with 1 in 7 not knowing their status (CDC, 2020). 
Among new cases of HIV transmissions there are racial disparities such that certain 
populations of color experience higher rates of HIV transmission compared to White 
populations. Black and Latinx populations are disproportionately affected, accounting for 
41% and 27% of new HIV infections in 2016, respectively (Goldstein et al., 2018). In 
2018, among Black populations, 
Figure 6 New HIV Diagnoses Among Black/African American people in the US and 





men accounted for the majority of these new cases: 79% from male-to-male sexual 
contact, 15% from heterosexual contact, 4% from injection needles, and 2% from 
combined male-to-male sexual contact and injection drug use. Among black women, 
most reported infections are due to heterosexual contact. (Figure 6; Center for Disease 
Control and Prevention, 2020). Among Latinx populations, men accounted for the 
overwhelming majority (85%) of new infections, with most reporting male-to-male 




In addition to racial disparities, factors such as sexual identity, language barriers, 
educational attainment, and socioeconomic status, play a significant role in HIV 
transmission. For instance, MSM may be at a higher risk for HIV transmission due to 
higher practice of anal intercourse. Evidence has shown that anal intercourse is associated  
with a higher transmission rate than vaginal intercourse, which can be attributed to the 
higher efficiency for HIV infection of the rectal mucosa (Beyrer et al., 2013).  
 
Education and Language and HIV 
Another factor in the high prevalence for HIV transmission is language barriers, which 
can serve as obstacles to healthcare as non-English speakers may not be able to 
FIGURE 7. New HIV Diagnoses Among Hispanics/Latinos in the US and Dependent 




communicate with their healthcare providers, and consequently may not receive HIV 
preventative care (Cooper et al., 2010). There is little research of an association between 
HIV and education level, but one study found that lower levels of educational attainment 
were predictors of higher HIV prevalence (Hargreaves & Howe, 2010). Educational 
attainment is often tied to socioeconomic status (SES). One study that examined the 
probability of an HIV positive test result and is association with SES found that lower 
SES was significantly associated with a higher probability of a HIV positive test result 
(Probst et al., 2017).  
 
Medical Mistrust 
Medical mistrust is the loss of trust within the healthcare system in regards to quality of 
care and physicians (Tekeste et al., 2019). Medical mistrust is deeply linked to racial 
injustices and negative behavior towards people based on social identity. For example, 
Black people are more likely to report a higher level of mistrust compared to White 
people (Tekeste et al., 2019). The presence of medical mistrust alone does have 
consequences on the health of those who experience in. In one study, Black MSM who 
experienced medical mistrust were less likely to attend their doctor appointments. 
Similarly, Black men and women were less likely to take their medication for HIV when 





While there is no cure for HIV, its immunosuppressive effects and transmissibility can be 
controlled with medication that minimizes production of the virus in an infected 
individual. The current course of suppressive treatment is combination antiretroviral 
therapy (cART), which includes at least two types of medications. Additionally, those 
who are HIV negative may prevent transmission by taking pre-exposure prophylaxis 
(PrEP) (Cihlar & Fordyce, 2016).  
 
The World Health Organization (WHO) especially recommends utilization of PrEP 
among high-risk groups. PrEP has been shown to have efficacy levels above 90% among 
individuals who have detectable serum levels of the drug (CDC, 2020). In another study, 
researchers were able to collect data from 1,600 HIV negative individuals in which more 
than 50% had received PrEP (Grant et al., 2014). The results of the study demonstrated 
that individuals with none or lower concentrations of the drug had increased incidences 
becoming HIV positive versus those with higher concentrations of the drug. In addition, 
the study results showed that those with higher concentrations of drug engaged with more 
sex partners, anal sex, and lesser frequency of condom use (Grant et al., 2014). Most of 
these studies have explored the effects of PrEP among MSM, however there is data that 
PrEP is beneficial for women as well (Thomson et al., 2016).  
 
The leading PrEP treatments are Truvada and Descovy, each having a similar biological 
mechanism for preventing HIV (De Clercq, 2016). The generic name for Truvada and 
Descovy is tenofovir disoproxil fumarate and tenofovir alafenamide, respectively. They 
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are nucleotide reverse transcriptase inhibitors that can insert themselves into the 
elongating chain of reverse transcriptase and terminate the viral DNA preventing 
replication (Anderson et al., 2011). While similar, their potency, lack of reaction to food, 
low effect of mitochondrial toxicity, and once daily use outweigh the disadvantages of 
the susceptibility to resistant mutants (Masho et al., 2007) 
 
In addition to PrEP treatments, there are other therapeutic agents for HIV negative 
individuals that target other stages of the HIV cycle. For example, Maraviroc is an oral 
pill take once a day that targets the CCR5 receptor of cells, and competitively inhibits 
HIV from binding to CD4+ cells (Abraham & Gulick, 2012). It has been shown to be 
concentrated within mucosal tissues, an area commonly targeted for HIV entry into the 
body (Abraham & Gulick, 2012). Another PrEP agent, raltegravir is also taken orally, 
however is classified as an integrase inhibitor. Other approved PrEP therapeutics involve 
subcutaneous injection that inhibit integrase and bind to CD4+ cells  (Abraham & Gulick, 
2012). 
 
While the effects of PrEP are promising, access to PrEP among marginalized groups is 
limited due to factors for higher risk of HIV transmission discussed above: language 
barriers, education, income, identity, race, and even social support. For example, Black 
women report poverty and employment as barriers to accessing PrEP (Nydegger et al., 
2020).  Gender and racial disparities intersect for transwomen’s access to PrEP such that 
trans women of color rate external barriers as more consequential to their access to PrEP 
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than do White trans women (Golub et al., 2013). Positive experiences with PrEP among 
Black and Latina transgender women have been linked to social support, while negative 
experiences have been linked to gender identity-based stigma (e.g., misconception that 
Black and Latina transgender women are all HIV positive) (Brooks et al., 2019). As 
discussed above, research has also found that Latinx communities often face language 
barriers when seeking HIV preventative treatment, such that patients lack English 
proficiency while healthcare providers often lack Spanish proficiency. Consequently 
these patients may not receive preventative treatment. (Dennis et al., 2011; Levison et al., 
2017; Painter et al., 2019; Rajabiun et al., 2008). 
 
Intimate Partner Violence 
Intimate partner violence (IPV) is violence that occurs within a romantic relationship. 
There are different forms of IPV, for example: physical abuse, sexual abuse, 
psychological abuse, and stalking (Breiding et al., 2015). According to the CDC, 1 in 4 
women and 1 in 10 men reported being abused in their lifetime (Breiding et al., 2015). 
IPV has been shown to have dramatic effects on a victims health and financial security 
(Breiding et al., 2015). For example, women have reported being restricted in using 
sexual health preventative treatment such as condoms. The reason for these limitations is 
to avoid conflict with their partner (e.g., due to assumptions of infidelity) (O’Malley et 
al., 2021). Additionally, women who experience recent events of abuse were less likely to 
adhere to preventative treatment (e.g., PrEP) (O’Malley et al., 2021). In another study, 
subjects were interviewed to discuss barriers towards receiving PrEP and reported that 
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they would disclose taking PrEP to their partner. However they expected negative 
reactions from their romantic partners, such as being called promiscuous or questioning 
their HIV status (Nydegger et al., 2020).  
 
Higher levels of IPV has been linked to certain groups, which similarly also experience 
higher levels of HIV transmission (Gielen et al., 2007). Black women specifically, are 
more likely not to report episodes of IPV compared to white women, particularly those 
who experience serious cases of abuse (Kelly et al., 2020). Gender based violence is 
evident among particular subgroups, such as female sex workers, transgender women, 
and woman with history of substance abuse (Leddy et al., 2019). Women in Tanzania 
who reported incidences of IPV were at a higher risk for becoming HIV positive (Dunkle 
& Decker, 2013). In one study, researchers described possibilities for HIV transmission 
among women experiencing IPV. Their findings demonstrated that IPV reduced a 
women’s mental health and ability for seeking sexual health prevention programs, 
resulting in chronic vulnerability states, and eventually becoming HIV positive (Dunkle 
& Decker, 2013).  
 
Minority Stress Model 
The minority stress model illustrates how identity related stressors experienced by sexual 
minorities impact their health and overall wellbeing (Figure 8, Meyer & Frost, 2013). 
Previous studies have evidence to support individuals who identify as gay or lesbian may 
experience more mental health issues (Cochran, 2001; Meyer, 2003). Meyer’s minority 
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stress model illustrates these stressors that go beyond the common stressors an individual 
may experience such as losing a job or the death of a loved one (Meyer, 2003). The 
model depicts stressors that are experience due to the individuals’ identity and position in 
society. These experiences include fear of rejection, internalized 
 
homophobia, and events of discrimination (Meyer, 2003). The minority stressors are also 
divided among being chronic, cultural, and social structures that are constant and social 
based stressors (e.g. social interaction; Meyer, 2003). 
 
Current Study  
Figure 8 Minority Stress Model in Gay, Lesbian, Bisexual People, I. H. Meyer, 2003 
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Although there is some data on HIV prevention and PrEP access among marginalized 
groups, there are significant gaps in the literature regarding the barriers transgender Black 
and Latinx men and women face in accessing PrEP. This study aimed to identify and 
examine the barriers commonly faced by Black and Latinx trans communities within the
 
 
Figure 9A Racial Identity Underrepresented Stress Model (URM) (Meyer, 2003) 
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state of Texas. Adapting both Meyer’s Minority Stress Model and Hendrick’s application 
of Gender Identity Stress Factors, we developed outcome-specific models for this study 
(Figure 9A; Figure 9B; Leddy et al., 2019).  Our adaptation of the minority stress model 
aimed to use gender and race as predictors of poor sexual health and lower probability of 
PrEP use among transgender Black and Latinx men. Previous researchers have found that 
higher rates of racial and gender discrimination are associated with lower likelihood of 
safer sexual practices (Graham, 2014). Furthermore, research indicates that lower rates of 
transphobia were linked with higher likelihood of safer sexual health practices and lower 
Figure 9B Gender Identity Underrepresented Stress Model (Adapted from Hendricks 
& Testa, 2012; Meyer, 2003 
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rates of HIV prevalence (Sugano et al., 2005). On the other hand, there is little data 
linking internalized racism and sexual health, but one study found that men who 
experience internalized racism were less likely to use condoms. There is some data to 
indicate that for transgender women of color in particular, financial insecurity may be 
associated with access to receiving HIV preventative care (Hotton et al., 2020).  
 
Data will be collected through an online or telephone survey with questions regarding 
participants’ socio-demographics and experiences with discrimination, internalized 
transphobia, internalized racism, medical mistrust, social support, PrEP knowledge, PrEP 
attitudes, and PrEP stigma. My hypotheses are based off the factors and predictors faced 
among MSM and cis black and Latinx men and women that I believe trans black and 
Latinx men and women will also experience.  
 
My predictions are separated into interpersonal barriers and systemic factors that are 
reflected in my survey questions. I predict that Black and Latinx transgender men and 
women with higher levels of education will have increased PrEP interest and use 
compared to individuals with lower levels of education, supported from previous data 
regarding education (Hargreaves & Howe, 2010). I anticipate transgender men and 
women of color who speak English fluently will have increased PrEP interest and uptake 
compared to individuals who are not fluent in English due to prevailing studies regarding 
language barriers as an obstacle to receiving HIV preventative care (Cooper et al., 2010). 
I also predict transgender men and women of color who endorse decreased medical 
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mistrust will have increased PrEP interest and use compared to individuals who have low 
levels of medical mistrust, which is supported by studies that evaluated transgender 
groups levels of medical mistrust and PrEP use (D’Avanzo et al., 2019). Lastly, I expect 
Black and Latinx transgender men and women with higher levels of social support will 
have increased PrEP interest and use compared to individuals with lower levels of social 
support, based off previous evidence on social support (Brooks et al., 2019). This study 
aims to fill in gaps in the literature and identify the obstacles transgender Black and 







Eligibility criteria for participants included identification as Black/African-American or 
Latinx; transgender: woman or man; 18-45 years old; in a relationship in the last 24 
months; and located in Texas. The projected recruitment sample was 50 black trans men 
and women and 50 Latinx trans men and women. Participants were recruited via flyers 
posted at clinics and community LGBTQ+ organizations within Texas as well as sending 
virtual flyers to organizations and community stakeholders. The survey was available in 
both English and Spanish and took 20 minutes to complete.  
 
Procedure 
The questions were developed on Qualtrics. The survey included questions of socio-
demographics, systemic, and interpersonal factors. Both survey and flyers were submitted 
and approved by the Institutional Review Board (IRB). Participants were consented at the 
beginning of the survey. There was a resource guide available for download on each page 
for contacts and links to PrEP services, counseling, and sexual health testing. At the end 
of the survey, participants were compensated with a $10 e-gift card of their choice via 
Tango.  
 
Measures              
Socio-demographics: age, race, gender identity, educational level, and income, were 
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measured using items adapted from a study examining the county level factors of HIV in 
Latino communities (Benbow et al., 2020).  
 
Language was defined as participants’ English proficiency and Spanish proficiency and 
assessed by asking if they understood and spoke Spanish. The language component also 
asked those with Spanish speaking abilities their experience with language in a medical 
setting and if their provider was able to understand them or spoke Spanish (Fernandez et 
al., 2011).  
 
Systemic discrimination was divided into social and structural components, using a four 
point Likert scale ranging from ‘never’ to ‘very often’ (Carliner et al., 2016; Hotton et al., 
2020). This component of the survey included questions about experiences with food 
insecurity, incarceration, obtaining healthcare, and employment.  
 
IPV Physical Abuse examined the individuals’ experience with different types of 
physical abuse from their partner and frequency of physical abuse (e.g. “my partner threw 
something at me”, “choked me”. Each of the possible physical abuse events were 
measured on a six point Likert scale ranging from ‘never’ to ‘once a day or more 
(Lehmann et al., 2012).  
 
IPV Sexual Abuse asked participants questions regarding the frequency and types of 
sexual abuse acts done by their partner. Some examples are “inflicted pain on me during 
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sex” and “Pressured or physically forced me to have sexual intercourse when I said no”. 
The answers were measured on a six point Likert scale ranging from ‘never’ to ‘once a 
day or more” (Lehmann et al., 2012) 
 
IPV Emotional Abuse was measured on a six-point Likert scale with options from ‘never’ 
to “once a day or more’. These questions examined acts of emotional abuse that occurred 
within the past year. Some examples are “Consistently blamed me for their problems or 
when they're jealous” and “Told me I was irrational or crazy” (Lehmann et al., 2012). 
 
IPV Economic Abuse explored acts of economic abuse committed by the participant’s 
partner. This was measured on a six-point Likert scale that examined the frequency of 
each act. Examples of these questions include “Did not allow me equal access to the 
family money or my money” and “Used my fear of not having access to money to control 
my behavior” (Lehmann et al., 2012) 
 
IPV Intimidation examined acts of intimidation, such as “Moved toward me with their 
hands raised when they were angry” and “Drove angrily or recklessly when I said stop” 
and their frequency (Lehmann et al., 2012). The responses were measured on a 6 point 
Likert scale with responses from ‘never’ to ‘once a day or more’.  
 
IPV Threats pertained to the frequency and acts of threats experienced by the participant. 
This was measured on a six-point Likert scale with responses from ‘never’ to ‘once a day 
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or more’. Examples of these questions include “Make sure I did not have money” and 
“Hit or kill me” (Lehmann et al., 2012) 
 
IPV Denying asked questions regarding acts of denial that are abusive and the frequency 
at which they were experienced by the participant. Examples of these questions are 
“Insisted that what they did was not so bad (normal for relationships)” and “Blamed me 
for his abusive behavior by saying it was provoked by some fault of mine” (Lehmann et 
al., 2012). Responses were measured on a six point Likert scale from ‘never’ to ‘more 
than once a day’. 
 
IPV Isolation section pertained to instances and acts in which the participant experienced 
feeling alone or distant by their partner. These questions included “Pressured me to stop 
contacting my family or friends” and “Did not allow me to do the things that he thought 
he had a right to do because he was a man” (Lehmann et al., 2012). This was measured 
on a six-point Likert scale with responses from ‘never’ to ‘once a day or more’. 
 
IPV Male Privilege examined experiences with male partners in which they may have 
abused participants due to their superiority based off their male gender. These questions 
included “Told me I couldn’t survive or get along without them” and “Did not allow me 
to do the things that he thought he had a right to do because he was a man” (Lehmann et 
al., 2012). This was measured on a six-point Likert scale ranging from ‘never’ to once or 
more a day’. 
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Internalized transphobia was measured using items adapted from a previous study on 
cisgender, sexual minority participants. The questions were rephrased to address 
transgender participants instead of cisgender and placed as a ‘select all that apply’. 
Examples of these questions included having the opportunity to become cisgender, being 
alienated because of being transgender, and avoiding social situations with other 
transgender people (Herek et al., 2009).  
 
Medical mistrust was measured using items on a five-point Likert scale with options from 
‘strongly agree’, to ‘strongly disagree’. Items assessed participants’ beliefs of mistakes 
commonly being made in the medical field, experiences with lack of patient privacy, 
and/or being misled by medical providers (Arnett et al., 2016).  
 
Social support was defined as “support accessible to an individual through social ties to 
other individuals, groups and the larger community” (Ozbay et al., 2007). Examples for 
measuring social support were given as a slider scale on the frequency of receiving social 
support from family and friends and also as a Likert scale measuring the participants 
satisfaction of social support received (Nemoto et al., 2011).  
 
PrEP knowledge was measured using 13 true/false items (e.g., “PrEP is a daily pill you 
take to reduce your risk of becoming infected with HIV”) (Walsh, 2019).  
PrEP attitudes were measured using 5 items on a 5 point Likert scale (e.g., “Taking PrEP 
is safe”) (Walsh, 2019).  
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PrEP stigma was measured using 5 items on a 5 point Likert scale (e.g., “People who take 
PrEP are promiscuous”) (Walsh, 2019).  
 
PrEP subjective norms measured belief in likelihood of support from social networks for 
PrEP use. It was measured using 4 items on a 5 point Likert scale (e.g., “My friends 
would be supportive of me using PrEP”) (Walsh, 2019).  
 
PrEP self-efficacy was measured using 8 items on a 5 point Likert scale (e.g., “How easy 
or difficult would it be for you to get tested for HIV?”) (Walsh, 2019)  
 
PrEP intentions and adoption measured likelihood of future PrEP use with 2 items on a 5 
point Likert scale (e.g., “Please select the likelihood of doing the following: in the next 3 
months I will get a prescription for PrEP”) (Walsh, 2019).  
 
PrEP barriers was measured using 9 items on a 5 point Likert scale where participants 
rated the importance of several factors that may serve as barriers to PrEP access (e.g., 
concern about side effects). The items were adapted from Walsh (2019). 
 
Statistical Analyses 
A power analysis determined a sample size of 100 black trans men and women and 
Latinx men and women participants. Transgender men will be oversampled to 
represented at least one-third of the sample. Analyses will be conducted using multiple 
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regression models to answer the research questions. Post-hoc analyses will explore 
differences between Black trans men and women, and Latinx men and women.  
 
Statistical analyses will be conducted using Stata v.15 (StataCorp, 2017). Preliminary  
analysis of variables will be conducted first to examine mean differences across 
sociodemographic variables and to explore correlations between variables. Preliminary 
analyses will also explore the extent of missing data to determine if other methods for 
handing missing data (e.g., multiple imputation or full maximum likelihood) would be 
appropriate. 
 
To examine the effects of interpersonal and systemic barriers on PrEP intentions and 
adoption among Black and Latinx Transgender individuals, multi-step regression 
analyses will be conducted. In the first model, PrEP intention and adoption will be 
regressed on PrEP self-efficacy, PrEP barriers, PrEP subjective norms, PrEP knowledge, 
PrEP attitudes, and PrEP stigma. If issues of multicollinearity arise from this model, I 
will explore whether separating these variables in multiple models or collapsing these 
variables will better serve the research questions to provide more interpretable results.  
 
Model 2 will examine sociodemographic factors and language; PrEP intentions and 
adoption will be regressed on age, race, gender identity, educational level, income, and 
language. Model 3 will examine interpersonal barriers; PrEP intentions and adoption will 
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be regressed on social support, medical mistrust, internalized transphobia, systemic 
discrimination.  
 
Model 4 will examine IPV; PrEP intention and adoption will be regressed on IPV 
Physical Abuse, IPV Sexual Abuse, IPV Emotional Abuse, IPV Economic Abuse, IPV 
Intimidation, IPV Threats, IPV Denying, IPV Isolation, IPV Male Privilege. If issues of 
multicollinearity arise from this model, I will explore whether separating these variables 
in multiple models or collapsing these variables will better serve the research questions to 











Anticipated results are expected to align with my proposed hypotheses. I expect both 
transgender men and women of color with higher levels of education will have higher 
rates of PrEP interest and uptake and contrarily, lower levels of education will have lower 
rates of PrEP interest and uptake. With regard to language, individuals who have a higher 
English proficiency will have more interest and uptake of PrEP compared to those who 
do not. In regard to medical mistrust, participants with higher rates and experiences with 
medical mistrust will have lower uptake and interest of PrEP. For social support, I expect 
higher levels of social support will have a significant influence on the participants interest 
and uptake of PrEP.  
 
In addition to my main hypotheses, I do expect income, age, and discrimination (both 
social and systemic) to be strong predictors for PrEP use. I do expect lower PrEP 
knowledge to be associated with individuals that answered the survey with lower levels 
of education, income, and PrEP interest. PrEP self-efficacy, attitudes and stigma will also 
be significant predictors for PrEP interest as lower levels of these parameters will 
indicate lower levels of PrEP interest and adoption. PrEP barrier answers that rated 
higher on importance will be associated with participants who indicated lower levels of 
income, education, and English fluency.  
 
With regard to IPV, I anticipate IPV Physical Abuse, IPV Sexual Abuse, IPV Emotional 
Abuse, IPV Economic Abuse, IPV Intimidation, IPV Threats, IPV Denying, IPV 
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Isolation, and IPV Male Privilege to all have varying significant associations with PrEP 
intentions and adoption, such that higher levels of IPV will predict lower PrEP intention 
and PrEP adoption. Further, I believe IPV Physical Abuse and IPV Sexual Abuse will 








The results of my study were not complete due to the pandemic and due to limited 
resources and time; however, it is the beginning for developing other studies 
investigating similar factors affecting Black and Latinx transgender men and women. 
What I had expected from my results will support the policy changes related to increased 
resources and patient directed care tailored to Black and Latinx trans men and women. 
My results will likely indicate that there is a need for more Spanish speaking physicians 
to prevent language barrier related disparities. With more Spanish speaking physicians, 
Latinx patients are able to communicate their needs, concerns and questions. It is 
important that Physicians are able to speak, write, and understand Spanish to avoid one-
way communications with their patients. 
 
Increased social support through outreach programs for transgender communities may 
lower internalized transphobia, which is linked to safer sexual practices, including, PrEP 
adoption. Resources such as counseling, LGBTQ+ groups, and programs that offer 
support to transgender Latinx and Black people should be implemented. These groups 
should offer opportunities for HIV counseling, therapy, and activities for other Black and 
Latinx transgender people to socialize.  
 
Policy changes should be implemented  to provide better care to Black and Latinx in all 
aspects of their health, such as insurance, HIV treatment/care/prevention, and domestic 
violence support. An example can be offering sexual health mobile clinics offering free 
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consultations for PrEP and sexual transmitted disease testing. These disparities can be 
addressed better by making these resources readily available to Black and Latinx trans 
men and women.  
 
Culturally competent physicians may also provide these groups with better opportunities 
for preventative care and better alleviate the issues and preconceived notions these groups 
have answered on this survey regarding medical mistrust. By having more culturally 
competent trainings for physicians will better identify those Black and Latinx trans men 
and women coming from lower socioeconomic communities. Physicians should be 
offered trainings and programs to better identify common resources needed for Black and 
Latinx transgender men and women. These trainings could include appropriate pronouns 
to address transgender people, understanding the disparities Black and Latinx trans men 
and women commonly experience, and providing information about PrEP.  
 
Limitations 
The limitations of this study included a small sample size, which limited the statistical 
power of the results and their generalizability. Further, our survey was conducted online 
due to the pandemic, rather than conducting in-person surveys, interviews, or focus 
groups. Our sample was limited to residents of Texas and therefore may limit its 
generalizability to other regions in the United States. In addition, the study participants 
were required to have internet, phone, email or other device to access the survey, thus 
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restricting participants who may not have had access to these technologies. Another 
limitation is extending the language barriers to other commonly spoken languages than 
Spanish, to broaden the sample size. Despite these limitations, this study will provide 
necessary insight into the barriers Black and Latinx transgender men and women face in 
accessing PrEP, an effective method of preventing HIV transmission.  
 
Conclusions and Future Directions 
I aimed to expand the current literature by examining barriers that had been previously 
researched only in cisgender and MSM populations. While there was insufficient data to 
draw conclusions, I strongly believe that this research will benefit future studies to 
explore these disparities even further. This study is a steppingstone to provide much 
needed knowledge in addressing the disparities faced among Black and Latinx trans men 
and women and their adoption of PrEP. Lastly, the hope is that with the completion of 
this study, the results can be applied and expanded upon at a larger scale, outside the state 







Thank you for your interest in taking our survey. This survey is voluntary and you are 
allowed to leave the study at any point. If you decide to complete this 20-minute survey, 
you will receive a $10 gift card of your choice via Tango and receive HIV, PrEP, IPV, 
and sexual health resources. No identifying information will be collected and your 
responses will be anonymous. If you have any questions or concerns, please contact the 
Gender Health Equity Lab at ghel@austin.utexas.edu or call or text (512) 489-6926. If 
you know anyone who may be interested in taking our study, please feel free to share our 




1. Please enter your age here: 































dd. 46+ (ineligible) 
2. Race/ethnicity: 
a. White (ineligible) 
i. West Asia (e.g., Armenia, Iraq, Israel, Lebanon, Turkey) 
ii. North Africa (e.g., Algeria, Egypt, Morocco, Sudan) 
iii. Europe (e.g., Germany, France, Ireland) 
iv. North Asia (e.g., Siberia, Russia 
b. Hispanic or Latino  
i. Central America (e.g., Costa Rica, El Salvador, Guatemala) 
ii. South America (e.g., Brazil, Colombia, Ecuador, Bolivia) 
iii. Mexico 
iv. Caribbean (e.g., Cuba, Puerto Rico, Dominican Republic) 
c. Black or African American 
i. Caribbean (e.g., Cuba, Haiti, Jamaica, Guyana) 
ii. South America (e.g., Brazil, Colombia, Ecuador, Bolivia) 
iii. North America (e.g., United States, Canada, Mexico) 
iv. North Africa (e.g., Algeria, Egypt, Morocco, Sudan) 
v. East Africa (e.g., Ethiopia, Kenya, Somalia, Uganda) 
vi. Central Africa (e.g., Angola, Cameroon, Democratic Republic of 
Congo) 
vii. West Africa (e.g., Ghana, Nigeria, Senegal, Sierra Leone) 
viii. Southern Africa (e.g., Botswana, Namibia, South Africa) 
d. Native American or American Indian (ineligible) 
e. Asian / Pacific Islander (ineligible) 
i. South Asia (e.g., Afghanistan, Bangladesh, Nepal, India, Pakistan) 
ii. East Asia (e.g., China, Taiwan, South Korea, Japan) 
iii. South-East Asia: (e.g.,Cambodia, Indonesia, Philippines, Thailand, 
Vietnam) 
iv. West Asia (e.g., Armenia, Iraq, Israel, Lebanon, Turkey) 
v. Central Asia (e.g., Kazakhstan, Kyrgyzstan, Tajikistan, 
Turkmenistan, Uzbekistan) 
vi. North Asia (e.g., Siberia, Russia) 
f. Other (please specify): 




b. No (including international and undocumented students) 
c. Prefer not to answer 
4. How would you describe your gender identity? 
a. Cisgender woman (female at birth and identify as female) (ineligible) 
b. Cisgender male (male at birth and identify as male) (ineligible) 
c. Trans woman (male-to-female) 
d. Trans man (female-to-male) 
e. Nonbinary or genderqueer (ineligible?) 
f. Questioning (ineligible?) 
g. Other (please specify): 
h. Prefer Not to Answer 









i. Other (please specify):  
j. Prefer not to answer 
6. What is the highest degree or level of education you have completed? 
a. Some High School 
b. High School 
c. Trade School 
d. Bachelor's Degree 
e. Master's Degree 
f. Ph.D., M.D, or equivalent 
g. Prefer not to say 
7. Have you been in a relationship in the past 24 months? 
a. Yes 
b. No (Ineligible) 
8. What is your current relationship status? 
a. Single 
b. In a steady or serious relationship 
c. In an ongoing relationship only involving physical or sexual contact 
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d. Not married but living with a romantic partner 
e. Married 
f. Divorced or separated 
g. Other (please specify): 
h. Prefer not to answer 






f. More than 6 
10. What is your annual household income (after tax)? 
a. Less than $10,000 
b. $10,000-$20,000 
c. $20,000 - $30,000 
d. $30,000 - $40,000 
















u. More than $200,000 
v. Prefer not to say 
11. What is your current employment status (Select all that apply)? 
a. Student 
b. Employed Full-Time 
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c. Employed Part-Time 
d. Looking for a job 
e. Retired 
f. Disability or SSI 
g. Unemployment or W2 
h. Other (please specify): 
i. Prefer not to say 







g. Other (please specify): 
h. Prefer not to say 






f. Other (please specify): 
g. Prefer not to say 
14. What state do you currently live in? 
a. Texas 
b. Any state other than Texas (ineligible) 
 
If Ineligible: Thank you for your time. Unfortunately, you are not eligible to continue 
with the remainder of the questionnaire. Here is a list of university, community, and 
national resources regarding HIV, PrEP, intimate partner violence, and sexual health. 
Right click on the list to download.  
 
If Eligible: Continue to Questionnaire 
1.Language Barriers1,2,3 
 
1) How often do you have difficulty understanding or speaking English?  




In the past 12 months, how often did you experience discrimination because of your race 
or the color of your skin in the following situations? Never, Sometimes, Fairly Often, 
Very Often  
1. Obtaining or treatment in health care  
2. Public settings, including on the street and in store or restaurants  
3. Obtaining a job or on the job  
4. Unemployed currently  
5. When getting admitted to a school or training program  
6. Ever incarcerated  
7. Food insecurity past 6 m 
8. Financial insecurity past 6 m 
9. Residential transience past 12 m 
10. Unstably housed currently 
11. When interacting with the courts or police  
12. When obtaining housing  
13. Called a racist name  
Internalized transphobia and Homophobia5  
IHP Scale Items5; adapted items are marked by*  
(Select all that apply to you)  
1. If someone offered me the chance to be completely heterosexual, I would accept 
the chance. 
2. If someone offered me the chance to be completely cisgender, I would accept the 
chance* 
3. I feel that being gay or lesbian/bisexual is a personal shortcoming for me. 
4. I feel that being transgender is a personal shortcoming for me* 
5. I would like to get professional help in order to change my sexual orientation 
from gay/lesbian/bisexual to straight. 
6. I would like to get professional help in order to change my gender identity from 
transgender to cisgender.* 
7. I often feel it best to avoid personal or social involvement with other individuals 
who identify as gay/lesbian. 
8. I often feel it best to avoid personal or social involvement with other transgender 
men or women.* 
9. I feel alienated from myself because of being gay or lesbian/bisexual. 
10. I feel alienated from myself because of being transgender.* 
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11. I wish that I could develop more erotic feelings about men/women (based on 
sexual identity). 
 
Medical Mistrust6  
Please rate your opinions when thinking about health care organizations, which include 
health clinics, hospitals, insurance companies, and public health departments (4-point 
Strong agree to Strongly disagree):  
1. You’d better be cautious when dealing with health care organizations.  
2. Patients have sometimes been deceived or misled by health care 
organizations.  
3. When health care organizations make mistakes they usually cover it up.  
4. Health care organizations sometimes have done harmful experiments on 
patients without their knowledge.  
5. Health care organizations don’t always keep your information totally private.  
6. Sometimes I wonder if health care organizations really know what they are 
doing.  
7. Mistakes are common in health care organizations.  
 
Social Support9,10  
Social support has been described as “support accessible to an individual through social 
ties to other individuals, groups, and the larger community (Faith, 2007).” We will ask 
you about the level of social support you may have received from family members, 
friends, and your community. 
 
1) Need for social support 
a) Range=1–3 (1=‘‘not at all’’; 2=‘‘need a little’’; 3=‘‘need quite a bit’’) 
2) Social support received from family members  
a) Range=1–5 (1=‘‘never’’; 5=‘‘almost every day’’). 
3) Social support received from transgender friends  
a) Range=1–5 (1=‘‘never’’; 5=‘‘almost every day’’). 
4) Social support received from non-transgender friends  
a) Range=1–5 (1=‘‘never’’; 5=‘‘almost every day’’). 
5) Satisfaction with social support from family members  
a) Range=1–3 (1=‘‘need a lot more’’; 2=‘‘need a little more’’; 3=‘‘it was 
about right’’). 
6) Satisfaction with social support from transgender friends.  
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a) Range=1–3 (1=‘‘need a lot more’’; 2=‘‘need a little more’’; 3=‘‘it was 
about right’’). 
7) Satisfaction with social support from non-transgender friends  






For each of the following questions, please choose True (T), False (F), or Don’t Know 
(DK).  If you do not know, please do not guess; instead, please choose Don’t Know. 
1.  PrEP is a daily pill you can take to reduce your risk of becoming infected with 
HIV. 
2. You should not use PrEP if you don’t know your HIV status. 
3.  If you do not take PrEP consistently, there may not be enough medicine in your 
bloodstream to block the HIV virus. 
4.  PrEP can be used to prevent STIs like gonorrhea, chlamydia, syphilis, herpes, 
and HPV. 
5. Many insurance plans will cover PrEP. 
6.  If you start taking PrEP, you will have to take it for the rest of your life. 
7. PrEP can be taken by people who already have HIV. 
8. There are ways to get PrEP even if you do not have insurance. 
9.  PrEP is available over-the-counter. 
10. You must take an HIV test every 3 months while taking PrEP. 
11.  There are many serious side effects of taking PrEP. 
12. The PrEP pill contains two medicines that are also used to treat HIV. 
13.  Daily PrEP use can lower the risk of getting HIV from sex by more than 90%. 
PrEP Attitudes11 
Do you agree or disagree with the following statements? 1=Strongly Disagree to 
5=Strongly Agree 
1.  PrEP is effective at preventing HIV. 
2. People who take PrEP are responsible. 
3. Taking PrEP is safe. 
4. It would be no trouble to take PrEP every day. 





Do you agree or disagree with the following statements? 1=Strongly Disagree to 
5=Strongly Agree 
1. People who take PrEP are promiscuous. 
2. Getting a PrEP prescription from a doctor would be embarrassing. 
3. If I were to take PrEP, I would be concerned if my friends found out I was taking 
it. 
4. If I were to take PrEP, I would be concerned if my family found out I was taking 
it. 
5. If I were to take PrEP, I would be concerned if my sexual partner(s) found out I 
was taking it. 
PrEP Subjective Norms11  
1=Strongly Disagree to 5=Strongly Agree 
 
1. My friends would be supportive of me using PrEP. 
2. My friends would think it was responsible if I used PrEP. 
3. My sexual partner(s) would be supportive of me using PrEP. 
4. My sexual partner(s) would think it was responsible if I used PrEP. 
 
 
 PrEP Self-Efficacy11 
Do you agree or disagree with the following statements? 1=Very Difficult to 5=Very 
Easy 
1. How easy or difficult would it be for you to seek out more information about 
PrEP to decide if it is right for you? 
2. How easy or difficult would it be for you to talk with your sexual partner(s) about 
the decision to take PrEP? 
3. How easy or difficult would it be for you to visit a doctor who can provide PrEP? 
4. How easy or difficult would it be for you to talk openly and honestly with a 
doctor about your sexual behaviors? 
5. How easy or difficult would it be for you get tested for HIV? 
6. How easy or difficult would it be for you to find a way to pay for PrEP? 
7. How easy or difficult would it be for you take a medicine like PrEP every day? 
8. How easy or difficult would it be for you to visit a doctor every three months for 




1=Definitely Will Not Do to 4=Definitely Will Do 
1. During the next three months, I will seek out more information about PrEP 
through a healthcare provider 
2. During the next three months, I will get a prescription for PrEP. 
 
PrEP Barriers12 
Please rate each barrier as: “1 Not at all important,” “2 Slightly Important,” “3 
Important,” “4 Fairly Important,” and “5 Very Important,” 
1. Concerns about the long-term effects of PrEP on my health 
2. Concerns about side effects 
3. Concerns that if I do become HIV+, certain medicines won’t work because I was 
taking PrEP 
4. Concerns that PrEP does not provide complete protection against HIV  
5. Having to take a pill everyday 
6. Concerns that having to take PrEP means I am putting myself at risk for HIV 
7. Concerns that PrEP might make my partner(s) expect me to have anal sex without 
a condom 
8. Concerns that people will see me taking medication and think I have HIV 
9. Having to talk to my doctor about my sex life 
End of Survey: 
We sincerely thank you for participating in our survey. If you would like to receive the 
$10 gift card, please click “continue”. You will receive a $10 gift card of your choice 
from Tango. This will take you to a new survey that will ask for your first name and e-
mail address in order to send you the $10. Because this is a separate survey, it will not be 
linked with your answers and your name and e-mail address will be deleted as soon as 
you redeem your gift card.  
 
You can click at the bottom of the survey to receive HIV PrEP, intimate partner violence, 
and sexual health resources. If you have any questions or concerns, please contact the 
Gender Health Equity Lab at ghel@austin.utexas.edu or call or text (512) 489-6926. If 
you know anyone who may be interested in taking our study, please feel free to share our 
flyer or survey link. 
 
Compensation Survey: 
Please enter your first name: 
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Please enter your e-mail address: 
 
Thank you again for participating! You will receive a $10 gift card of your choosing from 
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